Patients entered into the study will receive ASTX727 orally up to 3 to 8 days prior to
receiving Lutathera treatment to determine whether pre-treatment with ASTX727 results in
re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours.
The study will use [68Ga]-DOTA-TATE PET to image epigenetic modification of the receptor
locus.
Phase:
Phase 1
Details
Lead Sponsor:
Imperial College London
Collaborator:
Advanced Accelerator Applications, a Novartis company